BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.
BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance
January 20, 2022
Total 2021 Net Revenue expected in the range of $165 - $167 million , as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 - $148 million , as compared to previous guidance of $144-$148 million 2021 EBITDA expected to be in the $40 - $45 ...
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032
December 20, 2021
RALEIGH, N.C. , Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the U.S. ...
BioDelivery Sciences Reports Solid Third Quarter 2021 Results
November 3, 2021
Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential ...